Citations

Clear

273 citation(s) found for "Simone, N De".

TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Minnie, Simone A. , Waltner, Olivia G. , Zhang, Ping , Takahashi, Shuichiro , Nemychenkov, Nicole S, Ensbey, Kathleen S., Schmidt, Christine R. , Legg, Samuel R.W., Comstock, Melissa , Boiko, Julie R. , Nelson, Ethan , Bhise, Shruti S. , Wilkens, Alec B. , Koyama, Motoko , Dhodapkar, Madhav V. , Chesi, Marta , Riddell, Stanley R. , Spencer, Andrew , Green, Damian J , Spencer, Andrew , Furlan, Scott N , Hill, Geoffrey R , Koyama, Motoko , Hill, Geoffrey R.

Mayo Clinic

Science Immunology | April 19, 2024 | Volume: 9 | Issue: 94 | Pages: No page available

10.1126/sciimmunol.adg1094 | PMID 38640253 Get It

Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.
Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model
Hou, Jinchao , Chen, Yun , Cai, Zhangying , Heo, Gyu Seong , Yuede, Carla M. , Wang, Z , Lin, Kent , Saadi, Fareeha , Tršan, Tihana , Nguyen, Aivi T. , Constantopoulos, Eleni , Larsen, Rachel A. , Zhu, Yiyang , Wagner, Nicole D. , McLaughlin, Nolan, Kuang, Xinyi Cynthia, Barrow, Alexander D. , Zhou, Yingyue , Gilfillan, Susan , Gross, Michael L. , Brioschi, Simone , Liu, Yongjian , Wang, Zuoxu , Li, Dian , Zhou, Yingyue , Wang, Shoutang , Gilfillan, Susan , Gross, Michael L , Brioschi, Simone , Liu, Yongjian , Holtzman, David M , Colonna, Marco , Nguyen, Aivi T , Holtzman, David M. , Colonna, Marco

Mayo Clinic

Science Translational Medicine | April 3, 2024 | Volume: 16 | Issue: 741 | Pages: No page available

10.1126/scitranslmed.adj9052 | PMID 38569016 Get It

Microglia help limit the progression of Alzheimer’s disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4 , we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.
Current and Future Applications of Arterial Spin Labeling MRI in Cerebral Arteriovenous Malformations
Simone, Matteo De , Fontanella, Marco Maria , Choucha, Anis , Schaller, Karl , Machi, Paolo , Bijlenga, Philippe , Kurz, Felix T. , Maria, Lucio De , De Simone, Matteo , Bijlenga, Philippe , De Maria, Lucio , Fontanella, Marco Maria , Lanzino, Giuseppe , Lövblad, Karl‐Olof

Mayo Clinic

Biomedicines | March 28, 2024 | Volume: 12 | Issue: 4 | Pages: 753

10.3390/biomedicines12040753 | PMID 38672109 Get It

Arterial spin labeling (ASL) has emerged as a promising noninvasive tool for the evaluation of both pediatric and adult arteriovenous malformations (AVMs). This paper reviews the advantages and challenges associated with the use of ASL in AVM assessment. An assessment of the diagnostic workup of AVMs and their variants in both adult and pediatric populations is proposed. Evaluation after treatments, whether endovascular or microsurgical, was similarly examined. ASL, with its endogenous tracer and favorable safety profile, offers functional assessment and arterial feeder identification. ASL has demonstrated strong performance in identifying feeder arteries and detecting arteriovenous shunting, although some studies report inferior performance compared with digital subtraction angiography (DSA) in delineating venous drainage. Challenges include uncertainties in sensitivity for specific AVM features. Detecting AVMs in challenging locations, such as the apical cranial convexity, is further complicated, demanding careful consideration due to the risk of underestimating total blood flow. Navigating these challenges, ASL provides a noninvasive avenue with undeniable merits, but a balanced approach considering its limitations is crucial. Larger-scale prospective studies are needed to comprehensively evaluate the diagnostic performance of ASL in AVM assessment.
Abstract 37: IL-4 drives CART cell exhaustion in a CD4 independent manner
Stewart, Carli M. , Huynh, Truc , Mai, Long, Yun, Kun , Girsch, James H. , Feigin, Jennifer M. , Ruiz, Omar Gutierrez, Rodriguez, Makena, Ogbodo, Ekene J. , Sirpilla, Olivia , Xia, Hong , Kim, Jenny , Budka, Justin A. , Mattie, Mike , Filosto, Simone, Gutierrez-Ruiz, Omar L. , Stewart, Carli , Siegler, Elizabeth L. , Sakemura, Reona , Kimball, Brooke , Can, İsmail , Roman, Claudia Manriquez , Xia, Hong, Scholler, Nathalie , Kenderian, Saad S.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 37-37

10.1158/1538-7445.am2024-37 Get It

Abstract While chimeric antigen receptor T (CART) cell therapy has shown remarkable success, the development of exhaustion limits durable response. We identified a role for interleukin (IL)-4 in the development of CART cell exhaustion through three independent approaches including: 1) a genome-wide CRISPR knockout screen using healthy donor CART cells in an in vitro model for exhaustion, 2) RNA and ATAC sequencing on freshly produced and chronically stimulated healthy donor CART cells, and 3) RNA and ATAC sequencing on pre-infusion CART cell products from responders and non-responders in the Zuma-1 clinical trial that led to the FDA approval of axi-cel. Further, in vitro validation studies revealed that CD19 directed CART (CART19) cells chronically stimulated in the presence of human recombinant IL-4 (hrIL-4) displayed signs of exhaustion such as 1) decreased proliferation (p = 0.01), 2) increased coexpression of inhibitory receptors (p = 0.01), and 3) decreased production of IL-2 and interferon (IFN)-γ (p= 0.02, p = 0.002). Encouragingly, CART19 cells combined with an IL-4 monoclonal antibody improved antitumor activity (p = 0.045) and expansion (p = 0.01) while also decreasing the co-expression of inhibitory receptors (p = 0.02) in a mantle cell lymphoma xenograft mouse model. Building on these results, we asked if IL-4 driven exhaustion results from a direct impact of IL-4 on CART cells. To test this, we used a tumor-free assay where CART19 cells were chronically stimulated with CD19 beads in the presence of hrIL-4 or diluent. CART cells treated with hrIL-4 displayed an exhausted phenotype characterized by increased co-expression of inhibitory receptors (p = 0.04) and decreased production of IL-2 (p = 0.01). Next, we asked if IL-4 driven CART cell exhaustion is dependent on the costimulatory domain. We tested the impact of IL-4 on both CD28ζ and 41BBζ costimulated CART19 cells. Similar to our previous studies with CART19-28ζ cells, chronic stimulation of CART19-BBζ cells in the presence of hrIL-4 enhanced the exhausted phenotype as seen by increased co-expression of inhibitory receptors (p = 0.04) and decreased production of IL-2 and IFN-γ (p = 0.08 and p = 0.007). Finally, we asked if IL-4 induces exhaustion independently of its classic role in Th2 polarization of CD4 CART cells. Following CART production, we isolated CD8 cells and chronically stimulated them in the presence of hrIL-4 or diluent. CD8 CART cells treated with hrIL-4 displayed an enhanced exhausted profile as seen by 1) decreased proliferative ability (p < 0.0001), 2) increased co-expression of inhibitory receptors (p = 0.01), and 3) decreased production of IL-2 and IFN-γ (p < 0.0001, p = 0.004). Together, our data indicates a novel role for IL-4 in the development of CART cell exhaustion that is independent of tumor cells, costimulatory domain, and CD4 cells. As such, we believe IL-4 neutralization may be a widely applicable and actionable approach to improve the durable response to CART cell therapy. Citation Format: Carli M. Stewart, Elizabeth L. Siegler, Truc N. Huynh, R. Leo Sakemura, Brooke Kimball, Long Mai, Kun Yun, James H. Girsch, Jennifer Feigin, Omar Gutierrez Ruiz, Makena Rodriguez, Ekene Ogbodo, Ismail Can, Claudia Manriquez Roman, Olivia Sirpilla, Hong Xia, Jenny Kim, Justin Budka, Mike Mattie, Nathalie Scholler, Simone Filosto, Saad S. Kenderian. IL-4 drives CART cell exhaustion in a CD4 independent manner [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 37.
The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer
Deimling, Markus von , Mertens, Laura S. , Furrer, Marc A. , Li, Roger , Tendijck, Guus A. H. , Mari, Andrea , Tully, Karl H. , D’Andrea, David , Velev, Maud , Gallioli, Andrea , Albisinni, Simone , Mori, Keiichiro , Khanna, Abhinav, Rink, Michael , Fisch, Margit, Kiss, Bernhard , Collaborators, CLIPOLY Study Group, Antonelli, Alessandro , von Deimling, Markus , Furrer, Marc , Mari, Andrea , Pichler, Renate , Moschini, Marco , Tully, Karl H , D'Andrea, David , Laukhtina, Ekaterina , Del Giudice, Francesco , Gallioli, Andrea , Albisinni, Simone , Mori, Keiichiro , Lotan, Yair , Kiss, Bernhard , Antonelli, Alessandro , Li, Roger , Mertens, Laura S , Taylor, Jacob , Crocetto, Felice , Maas, Moritz , Pichler, Renate , Moschini, Marco , Laukhtina, Ekaterina , Marcq, Gautier , Minervini, Andrea , Black, Peter C. , Lotan, Yair , Spiess, Philippe E. , Shariat, Shahrokh F. , Pradère, Benjamin , Collaborators, CLIPOLY Study Group

Mayo Clinic

BJU International | March 12, 2024 | Volume: 134 | Issue: 1 | Pages: 119-127

10.1111/bju.16319 | PMID 38470089 Get It

Objective To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node‐positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. Patients and Methods We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose‐dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1–3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni‐ and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer‐specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. Results Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles ( P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2‐year OS estimates were 63% (95% confidence interval [CI] 0.53–0.74) and 63% (95% CI 0.58–0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni‐ or multivariable Cox regression analyses. Conclusion Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.
Structural bases for stoichiometry‐selective calcium potentiation of a neuronal nicotinic receptor
Mazzaferro, Simone , Kang, Guipeun , Natarajan, Kathiresan , Hibbs, Ryan , Sine, Steven M. , Hibbs, Ryan E

Mayo Clinic

British Journal of Pharmacology | March 8, 2024 | Volume: 181 | Issue: 13 | Pages: 1973-1992

10.1111/bph.16321 | PMID 38454578 Get It

Background and Purpose α4β2 nicotinic acetylcholine (nACh) receptors assemble in two stoichiometric forms, one of which is potentiated by calcium. The sites of calcium binding that underpin potentiation are not known. Experimental Approach To identify calcium binding sites, we applied cryo‐electron microscopy (cryo‐EM) and molecular dynamics (MD) simulations to each stoichiometric form of the α4β2 nACh receptor in the presence of calcium ions. To test whether the identified calcium sites are linked to potentiation, we generated mutants of anionic residues at the sites, expressed wild type and mutant receptors in clonal mammalian fibroblasts, and recorded ACh‐elicited single‐channel currents with or without calcium. Key Results Both cryo‐EM and MD simulations show calcium bound to a site between the extracellular and transmembrane domains of each α4 subunit (ECD‐TMD site). Substituting alanine for anionic residues at the ECD‐TMD site abolishes stoichiometry‐selective calcium potentiation, as monitored by single‐channel patch clamp electrophysiology. Additionally, MD simulation reveals calcium association at subunit interfaces within the extracellular domain. Substituting alanine for anionic residues at the ECD sites reduces or abolishes stoichiometry‐selective calcium potentiation. Conclusions and Implications Stoichiometry‐selective calcium potentiation of the α4β2 nACh receptor is achieved by calcium association with topographically distinct sites framed by anionic residues within the α4 subunit and between the α4 and β2 subunits. Stoichiometry‐selective calcium potentiation could result from the greater number of calcium sites in the stoichiometric form with three rather than two α4 subunits. The results are relevant to modulation of signalling via α4β2 nACh receptors in physiological and pathophysiological conditions.
Abstract 153: Pre‐procedural 3D visualization of deep‐learning vascular segmentation enhances identification of difficult femoral access in thrombectomy
Molina, Marc, Canals, Pere , Requena, Manuel , García‐Tornel, Álvaro , Molina, Marc, Tomasello, Alejandro , Li, Jiahui , Balocco, Simone , Díaz, Oliver , Ribó, Marc

Mayo Clinic

Stroke: Vascular and Interventional Neurology | March 5, 2024 | Volume: 3 | Issue: S2 | Pages: No page available

10.1161/svin.03.suppl_2.153 Get It

Introduction Difficult or impossible femoral access remains a significant burden for mechanical thrombectomy (MT) in stroke, affecting between 4.4% (impossible) to ∼10% of cases (time to first angiography [T1A] > 30 min) [1]. Visualization of CT angiography (CTA) or MR angiography are the only available diagnostic tools for neurointerventionalists (NIs) to qualitatively assess catheterization difficulty ahead of intervention. Visualization of 3D segmentation of the head‐and‐neck arteries from CTA may provide enhanced spatial information for catheter access difficulty assessment to the occlusion site, as well as large vessel occlusion (LVO) localization or carotid stenosis detection. Methods Three observers (2 expert NIs and 1 medical image engineer) assessed a sample of patients with anterior circulation stroke rating LVO location, femoral access difficulty according to a Likert scale (0 to 5) and assessment of radial access compared to femoral (easier or not). Raters were asked to answer the same form for each case twice, once after visualizing only the CTA and again after visualizing a deep‐learning, automated 3D segmentation of the head‐and‐neck arteries from CTA [2]. Cases were randomly sampled and blind to raters for both assessments. Likert scale values were normalized and averaged across observers, and correlation to T1A was studied. LVO localization accuracy and time needed for the analysis was also assessed. Results The final sample included N = 117 cases, where 22.98% presented difficult or impossible access. LVO location prevalence was 13/15/45/27% for extracranial ICA (eICA)/TICA/M1/M2, and 49/51% for right/left. Averaged Likert values presented significant linear correlation for both segmentation and CTA visualization, but this was much stronger in the former (R: 0.58 vs 0.30, p<0.001). Three‐dimensional visualization of segmented vessels allowed for an enhanced detection of difficult or impossible femoral access (ROC‐AUC: 0.85 vs 0.66). LVO detection was also superior after segmentation visualization (mean accuracy across observers: 0.81 vs 0.72) and time needed for assessment was on average 2.3 times shorter (44 s vs 100 s). In difficult or impossible patients, radial access was considered easier in 74% (63‐89%) of cases when visualizing the segmentation compared to 42% (35‐48%) when inspecting the CTA. Conclusion Visualization of deep‐learning 3D arterial segmentation resulted in enhanced difficult or impossible femoral access for MT, LVO detection and faster analysis over traditional pre‐procedural CTA inspection. Adding this visualization to the current workflow could enhance difficult access detection ahead of intervention.
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
Ravichandran, Naveen , Day, Jessica , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Patel, Aarat , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , M, Manesh Manoj, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Gaur, Prithvi Sanjeevkumar , Mamadapur, Mahabaleshwar , Ghodke, Akanksha, Kadam, Esha , Fazal, Zoha Zahid , Kardeş, Sinan , Yıldırım, Reşit, Maurier, F. , Meyer, Alain, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Lini, Daniele , Alluno, Alessia, Loarce‐Martos, Jesus , Aránega, Raquel, Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Mr Or, Nagy‐Vincze, Melinda , Schrieber, Karen, bouchti, Pr Imane El, Baba, Zineb, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Ouma Devi , Palalane, Elisa, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Harifi, Ghita, Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Quijivix, Daniel, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, M, Roberto Morales Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Agarwal, Vikas , Giollo, Alessandro , Gupta, Latika , Naveen, R , Day, Jessica , Nune, Arvind , Tan, Ai Lyn , Ziade, Nelly , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Knitza, Johannes , Pauling, John D , Wincup, Chris , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Lilleker, James B , Gheita, Tamer , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , De Angelis, Rossella , Hoff, Leonardo Santos , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Jagtap, Kshitij , Gracia‐Ramos, Abraham Edgar , Cavagna, Lorenzo , Chen, Yi‐Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Aggarwal, Rohit , Group, COVAD Study, Singh, Yogesh Preet , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Andréoli, Laura , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Prieto‐González, Sergio , Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Emorinken, Airenakho , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , So, Ho , Ugarte‐Gil, Manuel F. , Fathi, Hanan Mohamed , Mohammed, Reem Hamdy A , Harifi, Ghita , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | March 2, 2024 | Volume: 64 | Issue: 2 | Pages: 597-606

10.1093/rheumatology/keae128 | PMID 38430474 Get It

Abstract Objectives The objective of this study was to explore the prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIMs) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ≥14 days after two vaccine doses. We compared BI characteristics and severity among patients with IIMs, patients with other autoimmune rheumatic and non-rheumatic diseases (AIRD, nrAID), and healthy controls (HCs). Multivariable Cox regression models were used to assess the risk factors for BI, severe BI ,and hospitalizations among patients with IIMs. Results Among the 9449 included responses, BIs occurred in 1447 respondents (15.3%). The median age was 44 years [interquartile range (IQR) 21], 77.4% were female, and 182 BIs (12.9%) occurred among the 1406 patients with IIMs. Multivariable Cox regression among the data for patients with IIMs showed increasing age to be a protective factor for BIs [hazard ratio (HR) = 0.98, 95% CI = 0.97–0.99], and HCQ and SSZ use were risk factors (HR = 1.81, 95% CI = 1.24–2.64, and HR = 3.79, 95% CI = 1.69–8.42, respectively). Glucocorticoid use was a risk factor for a severe BI (HR = 3.61, 95% CI = 1.09–11.8). Non-white ethnicity (HR = 2.61, 95% CI = 1.03–6.59) was a risk factor for hospitalization. Compared with other groups, patients with IIMs required more supplemental oxygen therapy (IIMs = 6.0% vs AIRDs = 1.8%, nrAIDs = 2.2% and HCs = 0.9%), intensive care unit admission (IIMs = 2.2% vs AIRDs = 0.6%, nrAIDs and HCs = 0%), advanced treatment with antiviral or monoclonal antibodies (IIMs = 34.1% vs AIRDs = 25.8%, nrAIDs = 14.6% and HCs = 12.8%) and had more hospitalization (IIMs = 7.7% vs AIRDs = 4.6%, nrAIDs = 1.1% and HCs = 1.5%). Conclusion Patients with IIMs are susceptible to severe COVID-19 BIs. Age and immunosuppressive treatments were related to the risk of BIs.
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
Yoshida, Akira , Maroufy, Vahed , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Kadam, Esha , Goo, Phonpen Akawatcharangura , Milchert, Marcin , Dey, Dzifa , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Ziadé, Nelly , Kibbi, Lina El, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Vaidya, Binit , Yıldırım, Reşit, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Giollo, Alessandro, Fornaro, Marco, González, Raquel , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Gono, Takahisa , Tomaras, Stylianos, Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, F. , Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, Cristián, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Mendoza, Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Patel, Aarat , Tehozol, Erick Adrian Zamora , Chalico, Javier Merayo, Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Hasan, A T M Tanveer , Salim, Babur , Gupta, Latika , Kuwana, Masataka , Lilleker, James B , Day, Jessica , Milchert, Marcin , Dey, Dzifa , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Caballero-Uribe, Carlo Vinicio , Yoshida, Akira , De Angelis, Rossella , Li, Yuan , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Day, Jessica , Chen, Yi‐Ming , Saha, Sreoshy , Gracia‐Ramos, Abraham Edgar , Nune, Arvind , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Danieli, Maria Giovanna , Venerito, Vincenzo , Grignaschi, Silvia , Giollo, Alessandro, Alunno, Alessia , Iannone, Florenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Gonzalez, Raquel Aranega, Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Emorinken, Airenakho , Olaosebikan, Hakeem , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pauling, John D , Wincup, Chris , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Colunga-Pedraza, I. J. , Shumnalieva, Russka , Hoff, Leonardo Santos , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika

Mayo Clinic

Rheumatology Advances in Practice | February 29, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/rap/rkae028 | PMID 38524696 Get It

Abstract Objectives To investigate health-related quality of life in patients with idiopathic inflammatory myopathies (IIMs) compared with those with non-IIM autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs) and without autoimmune diseases (controls) using Patient-Reported Outcome Measurement Information System (PROMIS) instrument data obtained from the second COVID-19 vaccination in autoimmune disease (COVAD-2) e-survey database. Methods Demographics, diagnosis, comorbidities, disease activity, treatments and PROMIS instrument data were analysed. Primary outcomes were PROMIS Global Physical Health (GPH) and Global Mental Health (GMH) scores. Factors affecting GPH and GMH scores in IIMs were identified using multivariable regression analysis. Results We analysed responses from 1582 IIM, 4700 non-IIM AIRD and 545 nrAID patients and 3675 controls gathered through 23 May 2022. The median GPH scores were the lowest in IIM and non-IIM AIRD patients {13 [interquartile range (IQR) 10–15] IIMs vs 13 [11–15] non-IIM AIRDs vs 15 [13–17] nrAIDs vs 17 [15–18] controls, P &lt; 0.001}. The median GMH scores in IIM patients were also significantly lower compared with those without autoimmune diseases [13 (IQR 10–15) IIMs vs 15 (13–17) controls, P &lt; 0.001]. Inclusion body myositis, comorbidities, active disease and glucocorticoid use were the determinants of lower GPH scores, whereas overlap myositis, interstitial lung disease, depression, active disease, lower PROMIS Physical Function 10a and higher PROMIS Fatigue 4a scores were associated with lower GMH scores in IIM patients. Conclusion Both physical and mental health are significantly impaired in IIM patients, particularly in those with comorbidities and increased fatigue, emphasizing the importance of patient-reported experiences and optimized multidisciplinary care to enhance well-being in people with IIMs.
Clinicopathologic and Molecular Characteristics of Resected Thoracic Mass Lesions in the Pediatric Population: A 25-Year Institutional Experience From a Tertiary Care Center
Terra, Simone , Knight, Shannon M. , Kipp, Benjamin R. , Villalba, Julian A. , Terra, Simone Bsp, Pitel, Beth, Boland, Jennifer M. , Pitel, Beth A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 13, 2024 | Volume: 148 | Issue: 11 | Pages: 1209-1217

10.5858/arpa.2023-0251-oa | PMID 38347727 Get It

Context.— Primary thoracic neoplasms are rare in children, whereas nonneoplastic mass lesions or cysts and metastases are more common, and there is a relative paucity of comprehensive histopathologic and molecular data. Objective.— To define the clinicopathologic spectrum of neoplastic and nonneoplastic diseases observed in resected mass lesions in the chest of pediatric patients, and to identify somatic alterations observed in primary neoplasms. Design.— Clinicopathologic features of thoracic mass lesions (n = 385) resected from 373 patients aged ≤21 years in a 25-year period (1993–2018) were included. Primary neoplasms having sufficient material were tested by a laboratory-developed comprehensive genomic profiling assay that assesses tumor mutational burden, microsatellite instability, somatic sequence variants, gene amplifications, fusions, and specific transcript variants. Results.— The most commonly resected space-occupying lesions were nonneoplastic mass lesions and cysts or malformations, resected in 117 (31.4%) and 58 of 373 patients (15.5%) respectively. Metastatic neoplasms were observed in 169 of 373 patients (45.3%; mean age 14.4 years, range 1–21 years); the most common was osteosarcoma (68 of 169; 40.2% of metastases). Primary lung neoplasms occurred in 24 of 373 patients (6.4%; mean age 14.5 years, range 6 months–21 years), and 16 patients had primary extrapulmonary thoracic tumors. Carcinoid tumor was the most common primary lung neoplasm (7 typical, 3 atypical). Molecular testing showed a prevalence of somatic pathogenic or likely pathogenic mutations and copy-number alterations. No fusions or splice variants were identified. Tumors were microsatellite-stable with low tumor mutational burden. Conclusions.— Resected pediatric thoracic mass lesions are more likely to be metastatic lesions, congenital cysts or malformations, or nonneoplastic lesions compared to primary thoracic neoplasms, which are encountered at a low frequency and tend to have relatively simple genetic profiles.